Molecular dynamics insights for PI3K-δ inhibition & structure guided identification of novel PI3K-δ inhibitors

References

• Baell, J.B., & Holloway, G.A. (2010). New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. Journal of Medicinal Chemistry, 53(7), 2719–2740. doi:10.1021/jm901137j
   PubMed Web of Science ®Google Scholar
• Bochevarov, A.D., Harder, E., Hughes, T.F., Greenwood, J.R., Braden, D.A., Philipp, D.M., … Friesner, R.A. (2013). Jaguar: A high-performance quantum chemistry software program with strengths in life and materials sciences. International Journal of Quantum Chemistry, 113(18), 2110–2142. doi:10.1002/qua.24481
   Web of Science ®Google Scholar
• Brown, J.R., Byrd, J.C., Coutre, S.E., Benson, D.M., Flinn, I.W., Wagner-Johnston, N.D., … Furman, R.R. (2014). Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia. Blood, 123(22), 3390–3397.
   PubMed Web of Science ®Google Scholar
• Bulgaru, A.M., Mani, S., Goel, S., & Perez-Soler, R. (2003). Erlotinib (Tarceva): a promising drug targeting epidermal growth factor receptor tyrosine kinase. Expert Review of Anticancer Therapy, 3(3), 269–279. doi:10.1586/14737140.3.3.269
   PubMedGoogle Scholar
• Burris, H.A. (2004). Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. Oncologist, 9(3), 10–15.
   PubMedGoogle Scholar
• Callegari, D., Lodola, A., Pala, D., Rivara, S., Mor, M., Rizzi, A., & Capelli, A.M. (2017). Metadynamics simulations distinguish short- and long-residence-time inhibitors of cyclin-dependent kinase 8. Journal of Chemical Information and Modeling, 57(2), 159–169. doi:10.1021/acs.jcim.6b00679 Retrieved from https://doi.org/10.1021/acs.jcim.6b00679
   PubMed Web of Science ®Google Scholar
• Cantley, L. C. (2002). The phosphoinositide 3-kinase pathway. Science, 296(5573), 1655–1657. doi:10.1126/science.296.5573.1655
   PubMed Web of Science ®Google Scholar
• Cui, J.J., Tran-Dubé, M., Shen, H., Nambu, M., Kung, P.-P., Pairish, M., … Edwards, M.P. (2011). Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). Journal of Medicinal Chemistry, 54(18), 6342–6363. doi:10.1021/jm2007613
   PubMed Web of Science ®Google Scholar
• Friesner, R.A., Banks, J.L., Murphy, R.B., Halgren, T.A., Klicic, J.J., Mainz, D.T., … Shenkin, P.S. (2004). Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. Journal of Medicinal Chemistry, 47(7), 1739–1749. doi:10.1021/jm0306430
   PubMed Web of Science ®Google Scholar
• Grant, B.J., Rodrigues, A.P., ElSawy, K.M., McCammon, J.A., & Caves, L.S. (2006). Bio3d: an R package for the comparative analysis of protein structures. Bioinformatics, 22(21), 2695–2696. doi:10.1093/bioinformatics/btl461
   PubMed Web of Science ®Google Scholar
• Gross, S., Rahal, R., Stransky, N., Lengauer, C., & Hoeflich, K.P. (2015). Targeting cancer with kinase inhibitors. The Journal of Clinical Investigation, 125(5), 1780–1789.
   PubMed Web of Science ®Google Scholar
• Guo, Z., Mohanty, U., Noehre, J., Sawyer, T.K., Sherman, W., & Krilov, G. (2010). Probing the α-helical structural stability of stapled p53 peptides: molecular dynamics simulations and analysis. Chemical Biology & Drug Design, 75(4), 348–359. doi:10.1111/j.1747-0285.2010.00951.
   PubMed Web of Science ®Google Scholar
• Heffron, T.P., Heald, R.A., Ndubaku, C., Wei, B.Q., Augistin, M., Do, S., … Olivero, A.G. (2016). The rational design of selective benzoxazepin inhibitors of the alpha-isoform of phosphoinositide 3-kinase culminating in the identification of (S)-2-((2-(1-Isopropyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1, 4]oxazepin-9-yl)oxy)propanamide (GDC-0326). Journal of Medicinal Chemistry, 59(3), 985–1002. doi:10.1021/acs.jmedchem.5b01483
   PubMed Web of Science ®Google Scholar
• Jacobson, M.P., Pincus, D.L., Rapp, C.S., Day, T.J., Honig, B., Shaw, D.E., & Friesner, R.A. (2004). A hierarchical approach to all-atom protein loop prediction. Proteins: Structure, Function, and Bioinformatics, 55(2), 351–367. doi:10.1002/prot.10613
   PubMed Web of Science ®Google Scholar
• Jorgensen, W.L., Maxwell, D.S., & Tirado-Rives, J. (1996). Development and testing of the opls all-atom force field on conformational energetics and properties of organic liquids. Journal of the American Chemical Society, 118(45), 11225–11236. doi:10.1021/ja9621760 Retrieved from https://doi.org/10.1021/ja9621760
   Web of Science ®Google Scholar
• Jorgensen, W.L., & Tirado-Rives, J. (1988). The OPLS [optimized potentials for liquid simulations] potential functions for proteins, energy minimizations for crystals of cyclic peptides and crambin. Journal of the American Chemical Society, 110(6), 1657–1666. doi:10.1021/ja00214a001 Retrieved from https://doi.org/10.1021/ja00214a001
   PubMed Web of Science ®Google Scholar
• Liu, P., Cheng, H., Roberts, T.M., & Zhao, J.J. (2009). Targeting the phosphoinositide 3-kinase pathway in cancer. Nature Reviews. Drug Discovery, 8(8), 627–644.
   PubMed Web of Science ®Google Scholar
• Liu, Q., Shi, Q., Marcoux, D., Batt, D.G., Cornelius, L., Qin, L.-Y., … Tino, J.A. (2017). Identification of a potent, selective, and efficacious phosphatidylinositol 3-Kinase delta (PI3Kdelta) inhibitor for the treatment of immunological disorders. Journal of Medicinal Chemistry, 60(12), 5193–5208. doi:10.1021/acs.jmedchem.7b00618
   PubMed Web of Science ®Google Scholar
• Manley, P.W., Cowan-Jacob, S.W., Buchdunger, E., Fabbro, D., Fendrich, G., Furet, P., … Zimmermann, J. (2002). Imatinib: a selective tyrosine kinase inhibitor. European Journal of Cancer (Oxford, England : 1990), 38(5), S19–S27.
   PubMedGoogle Scholar
• Manning, G., Whyte, D.B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002). The protein kinase complement of the human genome. Science, 298(5600), 1912–1934. doi:10.1126/science.1075762
   PubMed Web of Science ®Google Scholar
• Pandey, B., Grover, S., Tyagi, C., Goyal, S., Jamal, S., Singh, A., … Grover, A. (2018). Dynamics of fluoroquinolones induced resistance in DNA gyrase of Mycobacterium tuberculosis. Journal of Biomolecular Structure and Dynamics, 36(2), 362–375. doi:10.1080/07391102.2016.1277784
   PubMed Web of Science ®Google Scholar
• Perry, M.W.D., Björhall, K., Bonn, B., Carlsson, J., Chen, Y., Eriksson, A., … Öster, L. (2017). Design and synthesis of soluble and cell-permeable PI3Kdelta inhibitors for long-acting inhaled administration. Journal of Medicinal Chemistry, 60(12), 5057–5071. doi:10.1021/acs.jmedchem.7b00401
   PubMed Web of Science ®Google Scholar
• Sacco, F., Perfetto, L., Castagnoli, L., & Cesareni, G. (2012). The human phosphatase interactome: An intricate family portrait. FEBS Letters, 586(17), 2732–2739.
   PubMed Web of Science ®Google Scholar
• Salam, N.K., Nuti, R., & Sherman, W. (2009). Novel method for generating structure-based pharmacophores using energetic analysis. Journal of Chemical Information and Modeling, 49(10), 2356–2368. doi:10.1021/ci900212v
   PubMed Web of Science ®Google Scholar
• Sastry, G.M., Adzhigirey, M., Day, T., Annabhimoju, R., & Sherman, W. (2013). Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. Journal of Computer-Aided Molecular Design, 27(3), 221–234. doi:10.1007/s10822-013-9644-8
   PubMed Web of Science ®Google Scholar
• Shivakumar, D., Williams, J., Wu, Y., Damm, W., Shelley, J., & Sherman, W. (2010). Prediction of absolute solvation free energies using molecular dynamics free energy perturbation and the opls force field. Journal of Chemical Theory and Computation, 6(5), 1509–1519. doi:10.1021/ct900587b
   PubMed Web of Science ®Google Scholar
• Singh, I., Singh, G., Verma, V., Singh, S., & Chandra, R. (2017). In Silico evaluation of variable ph on the binding of epidermal growth factor receptor ectodomain to its ligand through molecular dynamics simulation in tumors. Interdisciplinary Sciences, doi:10.1007/s12539-017-0265-0
   Google Scholar
• Skjaerven, L., Yao, X.-Q., Scarabelli, G., & Grant, B.J. (2014). Integrating protein structural dynamics and evolutionary analysis with Bio3D. BMC Bioinformatics, 15(1), 399. doi:10.1186/s12859-014-0399-6
   PubMed Web of Science ®Google Scholar
• Somoza, J.R., Koditek, D., Villaseñor, A.G., Novikov, N., Wong, M.H., Liclican, A., … McGrath, M.E. (2015). Structural, biochemical, and biophysical characterization of idelalisib binding to phosphoinositide 3-kinase delta. Journal of Biological Chemistry, 290(13), 8439–8446. doi:10.1074/jbc.M114.634683
   PubMed Web of Science ®Google Scholar
• Sonnenschein, C., & Soto, A.M. (2013). The aging of the 2000 and 2011 hallmarks of cancer reviews: A critique. Journal of Biosciences, 38(3), 651–663.
   PubMed Web of Science ®Google Scholar
• Sordella, R., Bell, D.W., Haber, D.A., & Settleman, J. (2004). Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science, 305(5687), 1163–1167. doi:10.1126/science.1101637
   PubMed Web of Science ®Google Scholar
• Terstiege, I., Perry, M., Petersen, J., Tyrchan, C., Svensson, T., Lindmark, H., & Öster, L. (2017). Discovery of triazole aminopyrazines as a highly potent and selective series of PI3Kdelta inhibitors. Bioorganic and Medicinal Chemistry Letters, 27(3), 679–687. doi:10.1016/j.bmcl.2016.11.004
   PubMed Web of Science ®Google Scholar
• Tiwary, P., Mondal, J., & Berne, B.J. (2017). How and when does an anticancer drug leave its binding site?. Science Advances, 3(5), e1700014. doi:10.1126/sciadv.1700014
   PubMed Web of Science ®Google Scholar
• Zhang, J., Yang, P.L., & Gray, N.S. (2009). Targeting cancer with small molecule kinase inhibitors. Nature Reviews Cancer, 9(1), 28–39. doi:10.1038/nrc2559
   PubMed Web of Science ®Google Scholar